THOMSON REUTERS
CORTELLIS™

Trevena Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 19-Jan-2015

THOMSON REUTERS
3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

Return to Table of Contents

THOMSON REUTERS

ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurateand validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

Return to Table of Contents

GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Return to Table of Contents

TABLE OF CONTENTS

Return to Table of Contents

Trevena Inc

COMPANY OVERVIEW

Company Name	Trevena Inc
Parent Company Name	Trevena Inc
Website	http://www.trevenainc.com/
Country	US
Number of Drugs in Active Development	4
Number of Inactive Drugs	5
Number of Patents as Owner	4
Number of Patents as Third Party	0
Number of Deals	7
Key Indications	Pain,Migraine,Cardiac failure,Depression,Parkinsons disease,Viral infection,Congestive heart failure,Myocardial infarction,Pre-
Key Target-based Actions	Opioid receptor mu agonist,Beta-arrestin inhibitor,Opioid receptor delta agonist,Opioid receptor kappa agonist,Unspecified GPCR modulator,Beta-arrestin stimulator,Angiotensin II AT-1 receptor agonist,Angiotensin II AT-1 receptor antagonist,Opioid receptor modulator,Opioid receptor delta modulator,Opioid receptor kappa modulator,Opioid receptor mu modulator
Key Technologies	Small molecule therapeutic,Intravenous formulation,Oral formulation,Capsule formulation,Peptide,Peptidomimetic

COMPANY PROFILE

SUMMARY

Trevena, a spin-out of Duke University is a drug discovery company focused on the development of G-protein coupled receptor-targeting pharmaceuticals.

LICENSING AGREEMENTS

In February 2009, Ligand entered into a 2-year agreement with Trevena, to screen Ligand's combinatorial compound library using Trevena's technology for 24 potential targets to develop as G-protein coupled receptor (GPCR) therapeutics. Trevena would be granted exclusive worldwide rights to sublicense active candidates resulting from the collaboration, and Ligand would receive payments based on progression of each chosen target.

EARLY R&D

In February 2010, the company was investigating three G-protein biased GPCR therapeutics for pain, which were in target validation, hit identification, and lead optimization, respectively.

By March 2008, Trevena had licensed a drug discovery platform from Duke University Medical Center.

FINANCIAL

In December 2014, the company intended to offer and sell $40 million of shares of its common stock in an underwritten public offering. Later that month, the company priced its offering of 11,250,000 shares of common stock at a price of US $4.00 per share raising the gross proceeds to around US $45 million. In addition, the company granted the underwriters a 30-day option to purchase 1,687,500 additional shares of common stock. The offering was expected to close on December 10, 2014; later that month, the company closed the offering and raised net proceeds of approximately $47.7 million through the sale of 12,848,000 shares in total including the the sale of an additional 1,598,000 shares of common stock to the underwriters pursuant to the partial exercise of the option.

In September 2014, the company entered into a senior secured term loan credit facility providing for up to $35 million of funding, with an interest rate of 6.5% per annum. A total of $2 million was drawn at closing. Trevena had the option to draw the remaining funds in two equal tranches of $16.5 million each, upon positive clinical data in the ongoing TRV-130 and TRV-027 studies. The maturity date for the credit facility was December 01, 2018. At the maturity date, a fee of between 5.25% and 7.0% of the amount borrowed would be due and under certain circumstances, the maturity date

Return to Table of Contents

might be extended to September 01, 2019.

In January 2014, the company announced the pricing of 8,500,000 shares of common stock priced at US $7.00 per share, and the underwriters were granted a 30-day option to purchase upto 1,275,000 additional shares at the same price. At that time, the offering was expected to close on February 05, 2014. Later that month, the company increased the number of common stock shares in the initial public offering to 9.25 million and priced the offering at $7 per share. The underwriters were granted a 30-day option to buy up to an additional 1,387,500 common stock shares at the same price. The shares began trading on the NASDAQ Global Market under the ticker symbol 'TRVN'. In February 2014, the IPO was closed. In March 2014, the underwriters over-allotment option was partially exercised and an additional 270,449 shares were purchased at a price of $7 per share. The offering was closed on March 06, 2014 with the total issue of 9,520,499 shares. Gross proceeds of approximately $67 million was raised.

In October 2013, Trevena proposed a initial public offering of shares of its common stock. the company also applied to list its common stock on the NASDAQ under the ticker symbol 'TRVN'.

In July 2010, Trevena completed a $35 million series B financing.

In March 2008, Trevena raised $24 million from a series A financing round.

R&D GRANTS

In November 2009, the National Institutes of Health (NIH) awarded Trevena a $7.65 million Grand Opportunity (GO) Grant to further fund the company's work to identify and characterize functionally selective biased GPCR ligands.

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart



Return to Table of Contents

Drugs by Indication Table

Indication	Active	Inactive	Total
Neurological disease	3	3	6
Genitourinary disease	0	1	1
Psychiatric disorder	1	0	1
Nutritional disorder	0	1	1
Cardiovascular disease	1	0	1
Inflammatory disease	0	1	1

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	2
Phase 1 Clinical	1
Discovery	1
No Development Reported	5

Return to Table of Contents

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Funding	2	0	0	0	2
Technology - Asset Divestment	0	0	1	0	1
Drug - Screening/Evaluation	1	0	0	0	1
Drug - Development/Commercialization License	1	0	0	0	1
Drug - Development Services	0	0	1	0	1
Technology - Target Validation	0	0	1	0	1

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Cardiovascular disease	1	5
Neurological disease	1	4

Trials by Phase

Phase	Ongoing	All
Phase 2	2	5
Phase 1	0	8

Phase Definitions

Phase 3 Clinical
Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical
Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical
Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Cardiovascular disease	2	0	2
Gastrointestinal disease	1	0	1
Ocular disease	1	0	1
Neurological disease	3	0	3

Return to Table of Contents

Respiratory disease	1	0	1
Infectious disease	2	0	2
Gynecology and obstetrics	1	0	1

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Return to Table of Contents

PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

TRV-130

TRV-130 SNAPSHOT

Drug Name	TRV-130
Key Synonyms	
Originator Company	Trevena Inc
Active Companies	Trevena Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Pain
Target-based Actions	Beta-arrestin inhibitor;Opioid receptor mu agonist
Other Actions	Analgesic
Technologies	Small molecule therapeutic;Intravenous formulation
Last Change Date	07-Jan-2015

TRV-130 DEVELOPMENT PROFILE

SUMMARY

Trevena is developing TRV-130 (TRV-130A), a G protein-biased mu opioid receptor ligand, and antagonizes the beta-arrestin pathway, for the potential iv treatment of post-operative pain , . In April 2014, a phase II bunionectomy trial was initiated in the US. In November 2014, top-line data were reported. In January 2015, a phase IIb trial was initiated. At that time, top-line data were expected in mid-2015 . In May 2014, the company was planning a phase III trial ; in January 2015, phase III trials were expected to begin in the first quarter of 2016. In March 2012, the company was seeking to outlicense TRV-130.

TRV-130 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Trevena Inc	Pain	US	Phase 2 Clinical	01-Apr-2014

TRV-130 CHEMICAL STRUCTURES

Return to Table of Contents

CAS Registry Number:	Confidence Level:
	3



Name	Type
TRV-130	Research Code

TRV-130 DRUG NAMES

Names	Type
TRV-130	Research Code
TRV-130A	Research Code

TRV-130 CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Pain											
0	0	0	0	1	3	0	0	0	0	1	3

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	1	3	0	3	0	0	1	6

Phase Definitions

Phase 3 Clinical
Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Return to Table of Contents

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

TRV-130 DEALS AND PATENTS

PATENTS

Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Trevena Inc	1	0	1

Return to Table of Contents

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Product	1

Return to Table of Contents

TRV-027

TRV-027 SNAPSHOT

Drug Name	TRV-027
Key Synonyms	
Originator Company	Ligand Pharmaceuticals Inc
Active Companies	Actavis plc;Trevena Inc
Inactive Companies	Forest Laboratories Inc;Ligand Pharmaceuticals Inc
Highest Status	Phase 2 Clinical
Active Indications	Cardiac failure
Target-based Actions	Beta-arrestin stimulator;Angiotensin II AT-1 receptor antagonist
Other Actions	Vasodilator;Cardioprotectant
Technologies	Biological therapeutic;Intravenous formulation;Infusion;Peptide
Last Change Date	12-Nov-2014

TRV-027 DEVELOPMENT PROFILE

SUMMARY

Trevena, (under license from Ligand Pharmaceuticals) presumed to be in collaboration with Actavis, following its acquisition of Forest Laboratories, is developing TRV-027 (TRV-120027), the lead peptide from a program of beta-arrestin biased GPCR ligands that inhibit the angiotensin II type 1 receptor, including TRV-120023, for the potential intravenous treatment of acute decompensated heart failure (ADHF),,,,,. In December 2010, a phase I/II trial in heart failure patients was initiated in the US ; in March 2012, the drug was in phase IIa development . By April 2012, a trial had been initiated in Poland and Czech Republic ; in October 2012, data from phase IIa trial were reported. In January 2014, the phase IIb BLAST-AHF trial was initiated in the US; in August 2014, data were expected in the fourth quarter of 2015. In March 2012, Trevena was seeking to outlicense TRV-027 .

TRV-027 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Actavis plc	Cardiac failure	US	Phase 2 Clinical	01-Jul-2014
Trevena Inc	Cardiac failure	Czech Republic	Phase 2 Clinical	13-Apr-2012
Trevena Inc	Cardiac failure	Poland	Phase 2 Clinical	13-Apr-2012
Trevena Inc	Cardiac failure	US	Phase 2 Clinical	31-Dec-2010
Ligand Pharmaceuticals Inc	Cardiac failure	US	Discontinued	08-Feb-2010

Return to Table of Contents

TRV-027 DRUG NAMES

Names	Type
TRV-120027	Research Code
beta-arrestin biased GPCR ligands (acute heart failure), Ligand/Trevena	
TRV-120023	Research Code
TRV-027	Research Code

TRV-027 CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Cardiac failure											
0	0	0	0	0	1	0	2	0	0	0	3
Acute decompensated heart failure											
0	0	0	0	1	1	0	0	0	0	1	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	1	2	0	3	0	0	1	5

Phase Definitions

Phase 3 Clinical
Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical
Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical
Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

Return to Table of Contents

TRV-027 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Trevena Inc	2	0	1	0	3
US Government	0	0	1	0	1
Ligand Pharmaceuticals Inc	1	0	0	0	1
Actavis plc	0	0	1	0	1

Return to Table of Contents

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	1	0	1
Drug - Development/Commercialization License	1	0	1
Technology - Target Validation	1	0	1

Return to Table of Contents

PATENTS

Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Trevena Inc	1	0	1
Actavis plc	1	0	1

Return to Table of Contents

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Product	1

Return to Table of Contents

TRV-734

TRV-734 SNAPSHOT

Drug Name	TRV-734
Key Synonyms	
Originator Company	Trevena Inc
Active Companies	Trevena Inc
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Pain
Target-based Actions	Opioid receptor mu agonist
Other Actions	Analgesic
Technologies	Oral formulation;Capsule formulation;Small molecule therapeutic
Last Change Date	12-Nov-2014

TRV-734 DEVELOPMENT PROFILE

SUMMARY

Trevena is developing TRV-734, a G-protein biased mu opioid receptor ligand as a follow-on program to the TRV-130, for the potential oral treatment of pain ,. In February 2014, a phase I trial was initiated for moderate to severe acute or chronic pain ; in June 2014, positive results were reported. In August 2014, phase II development was expected to begin. In March 2012, the company was seeking to outlicense the program after phase I,.

Trevena was previously investigating TRV-001 and TRV-002 for the potential oral treatment of pain. However, since November 2011, no development had been reported.

TRV-734 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Trevena Inc	Pain	US	Phase 1 Clinical	05-Feb-2014

Return to Table of Contents

TRV-734 DRUG NAMES

Names	Type
TRV-001	Research Code
TRV-002	Research Code
mu opioid receptor ligands (oral, pain), Trevena	
TRV-734	Research Code
TRV-130 follow-on compound, Trevena	

TRV-734 CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Pain											
0	0	0	0	0	0	0	1	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	0	2	0	0	0	2

Phase Definitions

Phase 3 Clinical
Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical
Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical
Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

Return to Table of Contents

TRV-734 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Trevena Inc	0	0	1	0	1
SCYNEXIS Inc	1	0	0	0	1

Return to Table of Contents

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development Services	1	0	1

Return to Table of Contents

TRV-250

TRV-250 SNAPSHOT

Drug Name	TRV-250
Key Synonyms	
Originator Company	Trevena Inc
Active Companies	Trevena Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Pain;Migraine;Depression;Parkinsons disease
Target-based Actions	Opioid receptor delta agonist
Other Actions	Antiparkinsonian;Antidepressant;Analgesic
Technologies	Oral formulation;Small molecule therapeutic
Last Change Date	15-Dec-2014

TRV-250 DEVELOPMENT PROFILE

SUMMARY

Trevena is investigating TRV-250, a lead from delta opioid receptor-biased ligands by using its Advanced Biased Ligand Explorer (ABLE) platform technology, for the potential oral treatment of major depressive disorder (MDD), pain including neuropathic pain, and other CNS indications such as Parkinson's disease and migraine,,. In December 2014, the program was in preclinical development. In March 2013, the company was seeking to outlicense the program.

Trevena was previously developing the program for the potential oral treatment overactive bladder. By December 2011, the program was in the lead-optimization stage. However in December 2014, no further development was reported for the indication.

TRV-250 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Trevena Inc	Depression	US	Discovery	20-Dec-2011
Trevena Inc	Migraine	US	Discovery	08-Jul-2014
Trevena Inc	Pain	US	Discovery	20-Dec-2011
Trevena Inc	Parkinsons disease	US	Discovery	20-Dec-2011
Trevena Inc	Overactive bladder	US	No Development Reported	15-Dec-2014

Return to Table of Contents

TRV-250 DRUG NAMES

Names	Type
delta opioid receptor ligands (pain/ depression/ Parkinson's disease/overactive bladder), Trevena	
delta opioid receptor ligands (oral, pain/ depression/ Parkinson's disease/overactive bladder), Trevena	
TRV-250	Research Code

TRV-250 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Trevena Inc	2	0	0	0	2
The Michael J. Fox Foundation	0	0	1	0	1
US Government	0	0	1	0	1

Return to Table of Contents

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	2	0	2

Return to Table of Contents

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:
http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

Return to Table of Contents